Current practice in the treatment of hyperlipidaemias

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 11, 2001, Pages 1777-1794

  Duriez, P ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Cholesterol; Fibrates; Hyperlipidaemia; Nicotinic acid; Resins; Statins

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; BILE ACID; CERIVASTATIN; CHOLESTEROL; CIPROFIBRATE; CLOFIBRATE; COLESTIPOL; COMPACTIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; ML 236 B; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLACEBO; PRAVASTATIN; RESIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONSTIPATION; CORONARY RISK; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ECONOMIC ASPECT; FLATULENCE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPOTHESIS; ISCHEMIC HEART DISEASE; JAUNDICE; LIPID ANALYSIS; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER DISEASE; LIVER FAILURE; MEDICAL DECISION MAKING; MOUSE; NAUSEA; NEUROPATHY; NONHUMAN; PANCREATITIS; PRIMARY PREVENTION; PRURITUS; RASH; RAT; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STOMACH PAIN; TREATMENT PLANNING; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; RISK FACTORS;

EID: 0035170397     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.11.1777     Document Type: Review

References (94)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
3. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
6. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
7. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
8. European Action on Secondary Prevention through Intervention to Reduce Events
9. Primary prevention of coronary heart disease: Guidance from Framingham: A statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association
10. Coronary heart disease: Reducing the risk: The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease
11. The Munster Heart Study (PROCAM). Results of follow-up at 8 years
12. The Diabetes Atherosclerosis Intervention Study (DAIS): A study conducted in cooperation with the World Health Organization. The DAIS Project Group
13. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a)
14. Small, Dense, Low-density Lipoprotein and Atherosclerosis
15. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the veterans affairs high-density lipoprotein intervention trial
16. High-density lipoprotein particles in octogenarians
17. Hypertriglyceridemia as a cardiovascular risk factor
18. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study
19. Lipoprotein(a), homocysteine, and remnant-like particles: Emerging risk factors
20. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study
21. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease
22. Nutritional intake of women and men on the NCEP Step I and Step II diets
23. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium
24. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
25. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
26. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women
27. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels
28. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
29. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
30. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol
31. A receptor-mediated pathway for cholesterol homeostasis
32. Sterols and isoprenoids: Signaling molecules derived from the cholesterol biosynthetic pathway
33. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
34. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
35. Transport-dependent proteolysis of SREBP: Relocation of site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi
36. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
37. The influence of short-term treatment with simvastatin on the inflammatory profile of patients with hypercholesterolaemia
38. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
39. The expression of proliferation and quiescence associated antigens in acute myeloid leukemia correlates with survival duration: Analysis of 15 refractory cases
40. The 4S study. Implications for prescribing
41. Statin drugs and dietary isoprenoids as antithrombotic agents
42. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation
43. The bezafibrate infarction prevention (BIP) study results
44. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT])
45. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
46. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
47. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay
48. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
49. The PPARs: From orphan receptors to drug discovery
50. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: The Italian multicenter study
51. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil
52. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
53. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators
54. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man
55. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate
56. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) for 23 days
57. Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia
58. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins
59. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E
60. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased ApoCIII and reduced ApoE on the particles
61. Further characterization of the metabolic properties of triglyceride- rich lipoproteins from human and mouse apoC-III transgenic mice
62. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
63. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition
64. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice
65. Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients
66. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: Additive effects of combination treatment on lipid regulation
67. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia
68. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels
69. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia
70. Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids
71. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor
72. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element
73. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice
74. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes: Role of the peroxisome proliferator-activated receptor- alpha
75. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response
76. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
77. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
78. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity
79. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
80. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients
81. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha
82. PPARalpha Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages
83. PPARalpha Activators Inhibit Tissue Factor Expression and Activity in Human Monocytes
84. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
85. The PPARα-leukotriene B4 pathway to inflammation control
86. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1
87. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
88. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
89. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
90. Carcinogenicity of lipid-lowering drugs
91. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
92. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
93. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol
94. Lipid intervention trials in diabetes